Georg Sczakiel

Prof. Dr. Georg Sczakiel

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2011 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
TLThomas Lavergne
Thomas Lavergne
CBCarine Baraguey
Carine Baraguey
CDChristelle Dupouy
Christelle Dupouy
NPNora Parey
Nora Parey
WWWinfried Wuensche
Winfried Wuensche
FDFrançoise Debart
Françoise Debart

11 May 2021 in Oncotarget
Verified
Journal Article
Open access
PDF file
JDJosephine Dubois
Josephine Dubois
JRJacqueline Rueger
Jacqueline Rueger
BHBernhard Haubold
Bernhard Haubold
RFRosel Kretschmer-Kazemi Far
Rosel Kretschmer-Kazemi Far
GSGeorg Sczakiel
Georg Sczakiel
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Josephine Dubois1, Jacqueline Rueger1, Bernhard Haubold2, Rosel Kretschmer-Kazemi Far1 and Georg Sczakiel1 1 Institut für Molekulare Medizin, Universität zu Lübeck and UKSH, Campus Lübeck, D-23538 Lübeck, Germany 2 Max-Planck-Institute for Evolutionary Biology, Department of Evolutionary Genetics, 24306 Ploen, Germany Correspondence to: Georg Sczakiel, email: georg.sczakiel@uni-luebeck.de Keywords: tumor diagnostics; non-invasive; urine RNA; biomarker; transcriptome analysis Received: March 17, 2021 Accepted: April 19, 2021 Published: May 11, 2021 Copyright: © 2021 Dubois et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Non-invasive clinical diagnostics of bladder cancer is feasible via a set of chemically distinct molecules including macromolecular tumor markers such as polypeptides and nucleic acids. In terms of tumor-related aberrant gene expression, RNA transcripts are the primary indicator of tumor-specific gene expression as for polypeptides and their metabolic products occur subsequently. Thus, in case of bladder cancer, urine RNA represents an early potentially useful diagnostic marker. Here we describe a systematic deep transcriptome analysis of representative pools of urine RNA collected from healthy donors versus bladder cancer patients according to established SOPs. This analysis revealed RNA marker candidates reflecting coding sequences, non-coding sequences, and circular RNAs. Next, we designed and validated PCR amplicons for a set of novel marker candidates and tested them in human bladder cancer cell lines. We identified linear and circular transcripts of the S100 Calcium Binding Protein 6 (S100A6) and translocation associated membrane protein 1 (TRAM1) as highly promising potential tumor markers. This work strongly suggests exploiting urine RNAs as diagnostic markers of bladder cancer and it suggests specific novel markers. Further, this study describes an entry into the tumor-biology of bladder cancer and the development of gene-targeted therapeutic drugs. <!--x2o[7a656725]-->

30 August 2021 in Cancers
Verified
Journal Article
Open access
PDF file
RFRosel Kretschmer-Kazemi Far
Rosel Kretschmer-Kazemi Far
KFKirsten Frank
Kirsten Frank
GSGeorg Sczakiel
Georg Sczakiel
Body fluids in the context of cancer diagnosis are the primary source of liquid biopsy, i.e., biomarker detection that includes blood and serum, urine, and saliva. RNA represents a particular class of biomarkers because it is thought to monitor the current status of gene expression in humans, in organs, and if present, also in tumors. In case of bladder cancer, we developed a scheme that describes, in detail, all steps from the collection of urine samples from patients, stabilization of samples, their transportation, storage, and marker analysis by qPCR-based technology. We find that urine samples prepared according to this protocol show stability of RNA over more than 10 days at unchilled temperatures during shipping. A specific procedure of primer design and amplicon evaluation allows a specific assignment of PCR products to human genomics and transcriptomics data collections. In summary, we describe a technical option for the robust acquisition of urine samples and the quantitative detection of RNA-based tumor markers in case of bladder cancer patients. This protocol is for general use, and we describe that it works for any RNA-based tumor marker in urine of cancer patients.

12 November 2021 in RNA Biology
Verified
Journal Article
Open access
SPSonja Petkovic
Sonja Petkovic
SGSarah Graff
Sarah Graff
NFNina Feller
Nina Feller
JBJulia Berghaus
Julia Berghaus
VRVanessa-Patricia Ruppert
Vanessa-Patricia Ruppert
GSGeorg Sczakiel
Georg Sczakiel
Circular RNA is progressively reported to occur in various species including mammals where it is thought to be involved in the post-transcriptional regulation of gene expression, partly via interactions with microRNA. Here, we asked whether the circular topology causes functional differences to linear forms when interacting with short RNA strands in vitro and in human cells. Kinetic studies with human bladder cancer-derived synthetic circular RNA versus linear transcripts, respectively, with short oligoribonucleotides showed similar association rates for both topologies. Conversely, a substantial topology-related difference was measured for the activation entropy and the activation enthalpy of RNA–RNA annealing. This finding strongly indicates a significant difference of the mechanism of RNA–RNA interactions. To investigate whether these characteristics of circular RNA are biologically meaningful we performed transient transfection experiments with a microRNA-regulated expression system for luciferase in bladder cancer-derived cells. We co-transfected linear or circular RNA containing one microRNA binding site for the target-suppressing microRNA mlet7a. Here, the circular isoform showed a strongly increased competition with microRNA function versus linear versions. In summary, this study suggests novel topology-related characteristics of RNA–RNA interactions involving circRNA in vitro and in living cells.

11 November 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JDJosephine Dubois
Josephine Dubois
GSGeorg Sczakiel
Georg Sczakiel
Numerous indirect and in silico produced evidences suggest circular RNAs (circRNA) in mammals while thorough experimental proofs of their existence have rarely been reported. Biological studies of circRNA, however, should be based on experimentally verified circRNAs. Here, we describe the identification of two circRNAs originating from the gene locus of the translocation associated membrane protein 1 (TRAM1). Linear and potentially circular TRAM1-specific transcripts were identified in a transcriptome analysis of urine RNA of bladder cancer (BCa) patients versus healthy donors. Thus, we first focused on the topology of TRAM1-specific transcripts. We describe conclusive experimental evidence for the existence of TRAM1-specific circRNAs in the human BCa cell lines ECV-304 and RT-4. PCR-based methodology followed by cloning and sequencing strongly indicated the circular topology of two TRAM1 RNAs. Further, studies with exon fusion sequence-specific antisense oligonucleotides (asON) and RNase H as well as studies in the use of RNase R contribute to conclusive set of experiments supporting the circular topology of TRAM1 transcripts. On the biological side, TRAM1-specific circRNAs showed low expression levels and minor differences in BCa cell lines while linear TRAM1 transcripts displayed down-regulated expression in the higher cancer stage model ECV-304 versus more differentiated RT-4 cells.

1 February 1998 in Blood
Verified
Journal Article
Open access
PDF file
RKRalf Kronenwett
Ralf Kronenwett
USUlrich Steidl
Ulrich Steidl
MKMichael Kirsch
Michael Kirsch
GSGeorg Sczakiel
Georg Sczakiel
RHRainer Haas
Rainer Haas
The use of antisense oligodeoxyribonucleotides (ODN) is a potential method to switch off gene expression. The poor cellular uptake of ODN in primary cells still is a limiting factor that may contribute to the lack of functional efficacy. Various forms of cationic lipids have been developed for efficient delivery of nucleic acids into different cell types. We examined the two cationic lipids DOTAP and DOSPER to improve uptake of ODN into primary human hematopoietic cells. Using a radiolabeled 23-mer, ODN uptake into blood-derived mononuclear cells could be increased 42- to 93-fold by DOTAP and 440- to 1,025-fold by DOSPER compared with application of ODN alone. DOTAP was also effective for delivery of ODN into leukocytes within whole blood, which may resemble more closely the in vivo conditions. As assessed by fluorescein isothiocyanate–conjugated ODN both cationic lipids enhanced cytoplasmic accumulation of ODN in endosome/lysosome-like structures with a partial shift of fluorescence to the whole cytoplasm and the nucleus following an incubation of 24 hours. ODN uptake by cationic lipids into different hematopoietic cell subsets was examined by dual-color immunofluorescence analysis with subset-specific monoclonal antibodies. We found a cell type–dependent delivery of ODN with greatest uptake in monocytes and smallest uptake in T cells. CD34+ cells, B cells, and granulocytes took up ODN at an intermediate level. Uptake of ODN into isolated CD34+cells could be increased 100- to 240-fold using cationic lipids compared with application of ODN alone. Stimulation of CD34+ cells by interleukin-3 (IL-3), IL-6, and stem cell factor did not significantly improve cationic lipid-mediated ODN delivery. Sequence-specific antisense effects in clonogenic assays could be shown by transfection of bcr-abl oncogene-directed antisense ODN into primary cells of patients with chronic myelogenous leukemia using this established protocol. In conclusion, cationic lipids may be useful tools for delivery of antisense ODN into primary hematopoietic cells. These studies provide a basis for clinical protocols in the treatment of hematopoietic cells in patients with hematologic malignancies and viral diseases by antisense ODN.